MBX Biosciences Clears FDA Hurdle for Phase 3 Trial of Once-Weekly Hypoparathyroidism Treatment

Event summary

  • MBX Biosciences completed an End-of-Phase 2 meeting with the FDA for once-weekly canvuparatide, a treatment for chronic hypoparathyroidism.
  • The Phase 3 trial will enroll approximately 160 patients, with a primary efficacy analysis at Week 26.
  • Canvuparatide received orphan drug designation from the EMA, supporting its clinical development in Europe.
  • The company plans to initiate the Phase 3 trial in Q3 2026.

The big picture

MBX Biosciences' successful End-of-Phase 2 meeting with the FDA marks a critical step in advancing its once-weekly treatment for chronic hypoparathyroidism. The Phase 3 trial design, informed by FDA feedback, aims to address the unmet medical need in a rare disease space with significant market potential. The orphan drug designation from the EMA further supports the company's international development strategy.

What we're watching

Regulatory Pathway
How the FDA's feedback will shape the Phase 3 trial design and potential NDA submission.
Market Opportunity
Whether canvuparatide can establish a new standard of care for hypoparathyroidism.
Execution Risk
The pace at which MBX Biosciences can enroll patients and complete the Phase 3 trial.